Sanofi-Aventis S.A. ADR SNY

$39.92 -0.75 (-1.84%)

Valuation

Market cap
98,601,360,000
Revenue TTM
$52,854,480,000
Net income TTM
$8,839,630,000
PE ratio
8.41
Forward PE
8.13
Profit margin
16.72%
Debt to equity
0.31

Trading

Volume
4,335,100
Avg volume
2,835,446
Day's range
$39.50 – $40.07
Shares out
2,424,425,000
Stochastic %K
13%
Beta
0.33
Analysts
Sell
Price target
$52.17

Price

Company profile

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and...

Show more

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
33 1 53 77 40 00
Website
https://www.sanofi.com
Address
46, avenue de la Grande ArmEe, Paris, France

Latest news

Stocktwits

KryptonResearch14 Oct 3, 9:58 AM
$REGN $SNY Sanofi is paying Regeneron 1 billion upfront for four long-acting antibodies meant to carry the franchise past Dupixent's patent cliff. The structure goes up to 8 billion total: 1 billion now, another 7 billion in milestones. The catch is timing. The lead asset (REGN20423, an IL-13 antibody for eczema) is still in Phase 1, and the other three don't reach the clinic until 2027. One level down, this is Sanofi buying the Dupixent sequel before it needs one. Dupixent protection starts lapsing in the early 2030s, so the 1 billion is a franchise-continuity premium on mostly preclinical assets. Costs and profits split 50/50, Regeneron runs R&D, Sanofi runs global sales. The deal also settles the 2024 lawsuit between the two. New Sanofi CEO Belen Garijo closed it in her first five months; her predecessor tried and failed to expand the alliance (per Barclays via Reuters).
0 replies
Cutlass Oct 2, 7:02 PM
$SNY Placed on watch - 52 week low triggered - 👀
1 replies
SparkyReturns Oct 2, 6:16 PM
$AMGN Just sharing: this is gonna change lives and the entire biopharma industry. Check out ICU. Their new device saves half of the people who would otherwise die from sepsis due to cytokine storm. Billions in TAM, about to roll out not just for kids but soon for adults in 2027 and no one realizes the import. 6 Breakthrough Device Designations ranging from Kidney, to Cardio, to Respiratory, cancer patients, infectious diseases... Unreal we can get in on the ground floor. $BMY $SNY $GSK $BIIB
0 replies
Stocktwits52wLows Oct 2, 2:30 PM
$SNY printed a new 52-week low today
0 replies
JackedNicholson Oct 2, 1:34 AM
$ALT Lean Mass Preservation, Weight loss, Tolerability, Easy/No titration, MASH, ALD, AUD, Glucagon, Franchise, Undervalued $NVO $MRK $LLY $SNY
3 replies
STUnusualVolume Oct 1, 5:15 PM
$SNY is trading at 3.1x its normal volume for this time of day.
0 replies
OpenOutcrier Oct 1, 12:33 PM
$REGN (+0.8% pre) $SNY Sanofi to invest up to $8BN to expand alliance with Regeneron https://ooc.bz/l/116185
0 replies
seven01trades Oct 1, 12:20 PM
$REGN $SNY — Confirmed $8B immunology expansion: Regeneron Pharmaceuticals and Sanofi expanded their long-running immunology partnership to cover four next-generation long-acting antibodies. Sanofi will pay Regeneron $1B upfront, with REGN eligible for up to another $7B in milestones. Future development/commercialization costs and profits will be shared 50/50. Sanofi One program, REGN20423, is already in Phase 1 for atopic dermatitis, with three additional antibodies expected to enter clinical trials in 2027. Importantly, the existing economics around blockbuster Dupixent remain unchanged. This is a substantial validation of Regeneron's next-generation immunology pipeline, not merely an early-stage research collaboration.
0 replies